You are here: Home: VP Audio Programs: VP BC 2 | 2008 Audio: VP BC 2 | 2008

To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Track 1	A 60-year-old woman underwent a mastectomy five years ago for a locally advanced, multiple node-positive, hormone receptor- positive, HER2-negative, infiltrating lobular carcinoma and received dose-dense AC paclitaxel, anastrozole and radiation therapy. After approximately four years, she presented with thrombocytopenia and a rising CA27.29 level. Bone marrow biopsy revealed an adenocarcinoma consistent with the breast primary.
Track 2	An 84-year-old woman was treated with radiation therapy and trastuzumab for a postmastectomy chest wall recurrence of an ER-negative, PR-negative, HER2-positive adenocarcinoma. After two years on trastuzumab, she developed a 3-cm axillary mass.
Track 3	A 67-year-old woman with a history 20 years ago of hormone receptor-positive breast cancer was diagnosed with bone and liver metastases. Biopsy revealed an ER-positive, PR-positive, HER2- negative adenocarcinoma consistent with the breast primary. The patient was treated on a clinical trial evaluating fulvestrant combined with bevacizumab.
Track 4	A 55-year-old woman with extensive prior anti-HER2 treatment including trastuzumab, lapatinib and the combination developed progressive abdominal pain and anorexia after receiving stereotactic radiation therapy for an isolated, progressive liver metastasis.
Track 5	A 48-year-old woman with hormone receptor-positive, HER2- negative breast cancer presented with extensive bone metastases, which were initially treated with hormonal therapy followed by nanoparticle albumin-bound (nab) paclitaxel/bevacizumab.